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ABSTRACT
CXCL14/BRAK (BRAK) is a secreted chemokine with anti-tumor activity, and its expression is 
suppressed in tumor cells. We previously reported the anti-tumor activity of BRAK in cell lines of 
head and neck squamous cell carcinoma (HNSCC) and the suppression of BRAK secretion in 
these cells. BRAK secretion in fibrosarcoma cells is restored by Fasudil, which is a Rho-kinase 
(ROCK) inhibitor. In this study, we examined the anti-tumor effect of BRAK by evaluating its 
gene expression and protein secretion in HNSCC cell lines. We found that BRAK mediated the 
suppressive effect of Fasudil against HNSCC cells. Tumor development in female BALB/cAJcl-
nu/nu mice was suppressed by Fasudil. Also secretion of BRAK protein by tumor cell lines in vi-
tro was significantly stimulated by Fasudil treatment. Similarly, the production of BRAK protein 
was significantly increased by the addition of Fasudil to cultured tumor cells. Furthermore Fasudil 
significantly increased BRAK gene expression at the mRNA level in HNSCC cell line. Inhibition 
of the RhoA/ROCK pathway by siRNAs significantly stimulated BRAK gene expression. These 
results show that the tumor-suppressive effect of Fasudil was mediated by BRAK, suggesting that 
Fasudil may therefore be useful for the treatment of HNSCC.
Head and neck squamous cell carcinoma (HNSCC) 
is the most frequent form of cancer in the head and 
neck region, with an estimated 644,000 cases world-
wide in 2012 and increasing every year (27, 28). 
HNSCC is generally treated surgically: however, 
large excisions require tissue transplantation and can 
affect the patients’ appearance and their ability to 
converse and eat, thus reducing their quality of life 
(QOL) (4, 26, 33). To improve QOL, it is important 
to reduce the tumor size with radiation or molecular 
targeted therapy prior to surgery (2, 34).
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the US National Institutes of Health Guide for the 
Care and Use of Laboratory Animals (NIH Publica-
tion No. 85-23, revised 1985), and the protocols 
were approved by the Institutional Animal Care 
Committee (Kanagawa Dental University, Yokosuka, 
Japan).
　BALB/cAJcl-nu/nu female mice were from Clea Ja-
pan (Tokyo, Japan). Fasudil (1-[5-isoquinolinesulfonyl]-
homopiperazine) from Tocris Bioscience (Bristol, 
UK) was used for in vitro experiments, and Fasudil 
hydrochloride from Asahi Kasei Pharma Co. (Tokyo, 
Japan) was used in vivo ones. Other reagents and 
their sources were as follow; bovine serum albumin, 
HEPES, trypsin, gentamicin, and EDTA, from Wako 
Pure Chemical Industries (Osaka, Japan); Dulbecco’s 
modified Eagle’s medium (DMEM), from Nissui 
Seiyaku (Tokyo, Japan); Fungizone, from Gibco (San 
Diego, CA, USA); siRentfect was from BIO-RAD 
(Hercules, CA, USA); fetal bovine serum (FBS), 
from Trance Scientific (Melbourne, Australia); Super 
Script II reverse transcriptase, TRIzol total RNA 
isolation reagent, SuperScript First-strand Synthesis 
system, and Zeocin, from Invitrogen (Carlsbad, CA, 
USA); PrimeSTAR DNA polymerase and EX Taq 
polymerase were from TaKaRa (Otsu, Japan); 
siRNA (RhoA: Hs_RHOA_7 HP Validated siRNA, 
ROCK1: Hs_ROCK1_9 HP Validated siRNA, 
ROCK2: Hs_ROCK2_6 HP Validated siRNA, and 
AllStars negative control siRNA), from QIAGEN 
(Venlo, Netherlands); SYBR Green qPCR Master 
Mix, from Agilent Technologies (Santa Clara, CA, 
USA); CXCL14 Duo Set ELISA Development Sys-
tem kit were from R&D Systems (Abington, UK); 
QuantaBlu Fluorogenic Peroxidase Substrate Kit, 
from Pierce (Rockford, IL, USA); Lumi-Light West-
ern blotting substrate, from Roche Diagnostics 
(Mannheim, Germany); and physiological saline, 
from Otsuka Pharmaceutical (Tokyo, Japan).
Cells and cell cultures. HNSCC cells such as HSC-
2, HSC-3 and HSC-4 were obtained from Riken 
Bioresource Center (Ibaraki, Japan). The cells were 
cultured in DMEM supplemented with 50 μg/mL 
gentamicin sulfate, 250 ng/mL Fungizone, 12.6 mM 
HEPES, and 10% FBS at 37°C under 5% CO2, and 
were subcultured following treatment with 0.25% 
trypsin. The cells were used within 3 to 4 passages 
and cell number was counted by using a Coulter 
Counter from Beckman Coulter (Brea, CA, USA).
Tumor growth in vivo. HSC-3 cells (2.0 × 106 cells/
site) were subcutaneously injected into both sides of 
the dorsolateral regions of 12 BALB/cAJcl-nu/nu fe-
　We previously reported that chemokine CXCL14/
BRAK (BRAK) suppresses vascularization and sup-
presses tumor formation in cell lines of HNSCC 
(20–22). BRAK was first identified in breast and 
kidney tissues, from which the protein got its name 
(7). Subsequently, BRAK was found to activate B 
cells and monocytes (29), as well as to attract den-
dritic cells to tumor tissues (24). BRAK also has 
anti-angiogenic activity, and induces apoptosis of tu-
mor cells (20). BRAK transcripts are abundant in 
normal tissues but are minimally expressed or absent 
in certain carcinoma cell lines (7). BRAK expres-
sion inhibits tumor vascularization and suppresses 
tumor development in BRAK transgenic mice (9, 13). 
We also showed that although BRAK is a secretory 
protein that possesses an N-terminal signal peptide 
sequence, BRAK secretion is suppressed in carcino-
ma cells (12). These findings suggest that induction 
of BRAK secretion in tumor cells may be an effec-
tive means for therapeutic treatment of tumors.
　We previously reported that the Ras-homologous 
small GTPase (RhoA) and its downstream effector 
Rho-kinase (ROCK) inhibit BRAK secretion in 
mouse fibrosarcoma cells (13). RhoA and ROCK 
play a central role in smooth muscle contraction, cy-
toskeleton rearrangement, cell migration, cell prolif-
eration, and gene expression (8, 11, 18). Secretory 
proteins and receptors are transported along micro-
tubules and actin fibers, which are downstream ef-
fectors of the RhoA/ROCK pathway (23). RhoA 
gene expression is enhanced in several tumors, in-
cluding HNSCC (1); thus, in general, excess activa-
tion of RhoA/ROCK causes aberrant localization of 
proteins and receptors in HNSCC.
　The ROCK-specific inhibitor Fasudil suppresses 
the growth of fibrosarcomas by increasing BRAK 
secretion (13). Also Fasudil modifies myosin light 
chain phosphorylation in smooth muscle cells (3, 
23). It was approved in Japan in 1995 for the clini-
cal treatment of vascular spasms in the brain (15). 
The safety of Fasudil has been confirmed in more 
than 1400 patients with subarachnoid hemorrhage 
(15). Fasudil may be useful as a molecular targeted 
therapy with few side effects for the treatment of 
cancers.
　In this study, we demonstrated that the ROCK-
specific inhibitor Fasudil suppresses HNSCC growth 
by stimulating BRAK expression and secretion.
MATERIALS AND METHODS
Materials and animals. The experimental procedures 
were performed in accordance with the guidelines of 
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Fasudil stimulated BRAK secretion in HNSCC cells
Cultured HSC-3 cells were treated with Fasudil at 
doses of 5–50 μM and cultured in serum-containing 
medium. After 24 h, BRAK secretion into the medi-
um was determined by performing an ELISA. 
BRAK secretion increased with an increase in the 
dose of Fasudil (Fig. 2A). The level of BRAK pro-
tein in the cell layer also increased with increase in 
dose (Fig. 2B). The amount of total (BRAK in the 
cell layer and that secreted into the medium) BRAK 
protein increased at the dose of 25 μM of Fasudil or 
higher (Fig. 2C). The BRAK secretion rate was cal-
culated as the ratio of secreted to cell-layer BRAK 
protein, and this rate increased when the cells treat-
ed with 25 μM of Fasudil or higher (Fig. 2D).
Fasudil increased mRNA levels of BRAK in HNSCC 
cells
Total BRAK protein levels increased with Fasudil 
treatment (Fig. 2C). To investigate the reason for 
this increase, we examined the effect of Fasudil in 
the gene expression of BRAK at the mRNA level. 
After 24 h treatment of cultured HSC-3 cells treated 
with Fasudil, we prepared RNA form the cells and 
analyzed their BRAK expression by performing 
qPCR. The results showed that BRAK gene expres-
sion in HSC-3 cells was stimulated with an increase 
in the Fasudil dose (Fig. 3), thus demonstrating that 
Fasudil promoted BRAK mRNA levels in these cells.
Inhibition of ROCK suppressed BRAK gene expres-
sion in HNSCC cells
We assessed the effect of ROCK and RhoA on the 
expression of BRAK mRNA in HSC-3 cells by per-
forming qPCR. Gene knockdown of RhoA, ROCK1, 
and ROCK2 by use of their respective siRNA was 
evaluated by comparison to the expression in con-
trol siRNA-transfected cells. In HSC-3, BRAK gene 
expression was induced by transfection with siRNA 
for RhoA, ROCK1, or ROCK2 (Fig. 4A). Similar 
results were obtained with HSC-2 cells derived from 
oral floor carcinoma and with HSC-4, tongue carci-
noma cell line (Fig. 4B, C).
DISCUSSION
In this study, we showed that Fasudil, a ROCK-spe-
cific inhibitor may be used for targeted molecular 
therapy of HNSCC. We previously reported that Fa-
sudil suppresses tumor growth by increasing BRAK 
secretion in fibrosarcoma cells (13). Fasudil also 
suppresses metastasis of and invasion by breast ade-
nocarcinoma cells (35). However, the mechanism by 
male mice. Tumor burden was established under the 
skin 2 days after injection; then, Fasudil dissolved in 
physiological saline (50 mg/kg/day) or vehicle was 
administered intraperitoneally (i.p.). Tumor volume 
was calculated according to the formula (a × b2) / 2, 
where a is the longest diameter of the tumor and b 
is the shortest diameter. Fifteen days after the start 
of Fasudil treatment, all mice were weighed and 
killed. Each tumor was subsequently removed and 
weighed.
Protein quantification. The culture medium was col-
lected and cells were dissolved in radio-immunopre-
cipitation assay (RIPA) buffer. BRAK protein was 
quantified with a CXCL14 Duo Set ELISA Devel-
opment System kit as described by the manufactur-
er, with minor modifications (9).
Reverse transcription and real-time quantitative PCR 
(qPCR) analyses. Total RNA was extracted with 
TRIzol reagent, reverse-transcribed with the Super-
Script First-strand Synthesis System, and amplified 
with ExTaq DNA polymerase. qPCR was performed 
with Brilliant SYBR Green qPCR Master Mix and 
the following primers: BRAK, 5’-AATGAAGCCAA 
AGTACCCGC-3’ (forward) and 5’-AGTCCTTTGC 
ACAAGTCTCC-3’ (reverse), which yielded a 232-
bp product; and beta-actin, 5’-AAAGACCTGTACG 
CCAACAC-3’ (forward) and 5’-CTCGTCATACTCC 
TGCTTGG-3’ (reverse), which yielded a 224-bp 
product. qPCR thermal cycling conditions were as 
follow; denaturation at 94°C for 30 s, annealing at 
58°C for 30 s, and extension at 72°C for 30 s.
RESULTS
Inhibitory effect of Fasudil on tumor growth of 
HNSCC cells
To examine the tumor-suppressive effect of Fasudil 
on HNSCC, first we inoculated female BALB/cAJcl-
nu/nu mice with HSC-3 cells. Tumor burden under 
the skin was established 2 days after injection. Then, 
Fasudil or vehicle was administered. Nine days after 
the beginning of Fasudil treatment, tumor growth 
was significantly suppressed by Fasudil treatment 
(Fig. 1A, C). After 15 days, all mice were weighed 
and killed. The weight of tumors from mice treated 
with Fasudil was significantly less than that of the 
vehicle treated tumors (Fig. 1D). Meanwhile, we ob-
served peritumoral vascularization and found that 
Fasudil treatment suppressed the neovascularization 
(Fig. 1B).
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Fig. 1　Inhibition of growth of HSC-3 tumor cells by Fasudil. (A) Representative photographs of Fasudil- and vehicle-treated 
(Control) mice. Areas surrounded with arrowheads indicate the position of tumors. (B) Vascular structure in tumor trans-
plants. Arrows indicate blood vessels. (C) Time-dependent effect of Fasudil on tumor growth. Vehicle-treated HSC-3 cells 
are indicated by closed circles; and those treated with Fasudil by open triangles. (D) Tumor weights after a 15-day treat-
ment with Fasudil. All values are shown as mean ± S.D. for 8 tumors. Significant differences between the vehicle and Fa-
sudil were determined by performing Student’s t-test *P < 0.05 and **P < 0.01.
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which Fasudil suppresses tumor development has 
not been defined in HNSCC. We first examined the 
tumor-suppressive effect of Fasudil on HNSCC after 
injecting HSC-3 cells into the dorsolateral regions 
of female BALB/cAJcl-nu/nu mice. Fasudil sup-
pressed HNSCC growth and peritumoral vascular-
ization (Fig. 1A–D). We previously reported that 
peritumoral BRAK inhibits vascularization and sup-
presses tumor growth (9). These findings suggest tu-
mor progression would be accelerated by inhibition 
of BRAK protein secretion by tumor cells.
　To characterize the mechanism of tumor suppres-
sion by Fasudil treatment, we investigated the effect 
of Fasudil treatment on the secretion of BRAK pro-
tein. HSC-3 cells were treated with Fasudil and in-
cubated in serum-containing culture medium for 
24 h, and then the amounts in the cell layer and me-
dium were determined. BRAK protein secretion 
from HSC-3 cells was increased by Fasudil used at 
a 25 μM of concentration or higher (Fig. 2A). Simi-
larly, the levels of BRAK protein in the cell layer 
and the total amount (in both cell layer and medi-
um) were increased at dose of Fasudil 25 μM and 
higher (Fig. 2C). These results show that the total 
amounts of BRAK protein increased by Fasudil at 
dose of 25 μM or higher (Fig. 2D). These results 
suggest that Fasudil increased both the total amount 
of BRAK protein and secretion of BRAK protein in 
cell lines of HNSCC.
　We previously demonstrated that the ROCK-specif-
ic inhibitor Fasudil increases BRAK secretion in fi-
brosarcoma cells (13); however, the effect of Fasudil 
on BRAK gene expression had not been character-
ized. We previously reported that activation of epider-
mal growth factor receptor (EGFR) signaling pathway 
suppresses BRAK gene expression in HNSCC (20–
22), and others have shown that endocytosis of 
EGFR is inhibited by activation of RhoA/ROCK 
pathway (17). This might be one of the reasons that 
EGFR was overexpressed in several tumor cells, in-
cluding HNSCC cells (10, 20, 31). Thus, we hypoth-
esized that inhibition of RhoA/ROCK by Fasudil 
Fig. 2　Dose-dependent effects of Fasudil on the production and secretion of BRAK. HSC-3 cells (2.0 × 105 cells/35-mm 
dish) were treated with varying concentrations of Fasudil (0, 5, 10, 25, and 50 μM) for 24 h. (A–C) BRAK protein secreted 
in the culture medium (A), BRAK protein remaining in the cell layer (B), and total BRAK protein (culture medium plus cell 
layer (C) are shown. (D) Relative amounts of BRAK protein in the culture medium and cell layer. The columns and bars 
represent means ± S.D. of triplicate assays. Significant differences between treatments were determined by performing Stu-
dent’s t-test: *P < 0.05 and **P < 0.01.
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sudil and found that HSC-3 cells were induced 
amount of BRAK at the mRNA level in the pres-
ence of Fasudil (Fig. 3).
　The results suggest that ROCK and RhoA regu-
late BRAK gene expression in cell lines of HNSCC 
(Fig. 3). Therefore, we examined BRAK gene expres-
sion in cells transfected with siRNAs for ROCK1, 
ROCK2, and RhoA. In HSC-3 cells, BRAK gene 
expression was elevated by suppressing expression 
of RhoA, ROCK1, and ROCK2 (Fig. 4A). Similar 
results were obtained with HSC-2 and HSC-4 cells 
(Fig. 4B, C). Fasudil is known to suppress activation 
of ROCK1 and ROCK2 in several tumor cells (14). 
Our results show that BRAK gene expression was 
induced by siRNA-mediated inhibition of the RhoA/
ROCK pathway.
　Tumor progression has multiple stages and de-
pends on the balance of tumor suppressing and tu-
mor-promoting genes (5, 25, 32). Overexpression of 
the RhoA/ROCK pathway occurs and is involved in 
invasion by and metastasis of several types of tumor 
cells (16, 19). Our present study showed that inhibi-
tion of the RhoA/ROCK pathway suppressed tumor 
progression by increasing the expression of the anti-
tumor chemokine BRAK gene and the level of its 
secreted protein. In Japan, Fasudil is used for the 
clinical treatment of cerebral vasospasms after sub-
arachnoid hemorrhage, and its safety has been con-
firmed in more than 1,400 patients (3, 6), with no 
may stimulate expression of the anti-tumor chemo-
kine BRAK. Therefore, we examined BRAK gene 
expression in cell lines of HNSCC treated with Fa-
Fig. 3　Effect of Fasudil concentration on BRAK gene ex-
pression. HSC-3 cells (2.0 × 105 cells/35 mm dish) were 
treated with varying concentrations of Fasudil (0, 5, 10, 25, 
and 50 μM) for 24 h. Levels of BRAK mRNA per GAPDH 
mRNA (endogenous standard) were calculated, and the 
value obtained from the cultured cells without Fasudil was 
set 100%. Columns and bars represent means ± S.D. of 
triplicate assays. Significant differences were determined by 
performing Student’s t-test *P < 0.05 and **P < 0.01.
Fig. 4　Stimulation of BRAK expression by siRNA treatment. HNSCC cells (2.0 × 105 cells/35 mm dish) were inoculated into 
culture dishes containing DMEM-10, cultured for 12 h, and then transfected with siRNAs for RhoA, ROCK1, ROCK2, or 
control siRNA for 24 h. BRAK gene expression in HSC-3 cells (A), HSC-2 cells (B) and HSC-4 cells (C) are shown. Col-
umns and bars represent means ± S.D. of triplicate assays. Significant differences were assessed by performing Student’s t-
test *P < 0.05 and **P < 0.01.
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reported drug-associated deaths (30). These reports 
support the potential clinical utility of Fasudil in 
HNSCC.
　In conclusion, the ROCK-specific inhibitor Fasudil 
promoted BRAK gene expression and protein secre-
tion in HNSCC cells. Furthermore, Fasudil showed 
anti-tumor activity via angiostatic activity in vivo. 
These results suggest that Fasudil may offer thera-
peutic benefit via targeted RhoA/ROCK signaling in 
HNSCC. In the future, Fasudil can be used as a mo-
lecular target drug that has only a few side effects 
for the treatment of HNSCC. Further studies will 
define the mechanism of the anti-tumorigenic activi-
ty of Fasudil.
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